Clinical Trial News and Research

RSS
Comprehensive care improves health of high-risk, chronically ill children, reduces hospital costs

Comprehensive care improves health of high-risk, chronically ill children, reduces hospital costs

PTC begins rolling NDA submission for Translarna to treat nmDMD

PTC begins rolling NDA submission for Translarna to treat nmDMD

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

EMA validates Synageva's sebelipase alfa MAA for LAL Deficiency

EMA validates Synageva's sebelipase alfa MAA for LAL Deficiency

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Using laparoscopy for VP shunt placement can decrease rate of distal shunt failures

Using laparoscopy for VP shunt placement can decrease rate of distal shunt failures

Medical researchers at Saint Louis University bring hope to those in pain and sickness

Medical researchers at Saint Louis University bring hope to those in pain and sickness

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Multicenter, clinical trial to address long-term complications in CKD patients

Multicenter, clinical trial to address long-term complications in CKD patients

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Intra-arterial stroke treatment more effective than medical management with tPA, study finds

Intra-arterial stroke treatment more effective than medical management with tPA, study finds

Research outlines new model for measuring acceptability of contraceptive vaginal ring

Research outlines new model for measuring acceptability of contraceptive vaginal ring

Health promotion program reduces cardiovascular risk in obese people with serious mental illness

Health promotion program reduces cardiovascular risk in obese people with serious mental illness

New intervention combines social media with behavioral psychology to encourage more HIV testing

New intervention combines social media with behavioral psychology to encourage more HIV testing

Investigational drug increases PFS in patients with advanced breast cancer

Investigational drug increases PFS in patients with advanced breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.